LLY

1,018.34

-1.37%↓

JNJ

243.3

-0.64%↓

ABBV

225.58

-0.57%↓

NVS

165.87

-0.78%↓

MRK

119.81

-2.53%↓

LLY

1,018.34

-1.37%↓

JNJ

243.3

-0.64%↓

ABBV

225.58

-0.57%↓

NVS

165.87

-0.78%↓

MRK

119.81

-2.53%↓

LLY

1,018.34

-1.37%↓

JNJ

243.3

-0.64%↓

ABBV

225.58

-0.57%↓

NVS

165.87

-0.78%↓

MRK

119.81

-2.53%↓

LLY

1,018.34

-1.37%↓

JNJ

243.3

-0.64%↓

ABBV

225.58

-0.57%↓

NVS

165.87

-0.78%↓

MRK

119.81

-2.53%↓

LLY

1,018.34

-1.37%↓

JNJ

243.3

-0.64%↓

ABBV

225.58

-0.57%↓

NVS

165.87

-0.78%↓

MRK

119.81

-2.53%↓

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Отворен

4.4 0.46

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.37

Максимум

4.4

Ключови измерители
By Trading Economics
Служители	26

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	13M 34M
Предишно отваряне	3.94
Предишно затваряне	4.4

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.02.2026 г., 23:25 ч. UTC

Горещи акции

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25.02.2026 г., 23:15 ч. UTC

Печалби

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25.02.2026 г., 23:54 ч. UTC

Пазарно говорене

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25.02.2026 г., 23:47 ч. UTC

Печалби

Ferrovial 4Q Net EUR197M >FER.MC

25.02.2026 г., 23:45 ч. UTC

Печалби

Ferrovial 4Q Rev EUR2.72B >FER.MC

25.02.2026 г., 23:42 ч. UTC

Печалби

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25.02.2026 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Company's Business Operations Remain Normal >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY EPS CNY47.67 >TCOM

25.02.2026 г., 23:06 ч. UTC

Печалби

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25.02.2026 г., 23:01 ч. UTC

Печалби

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25.02.2026 г., 23:00 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

25.02.2026 г., 23:00 ч. UTC

Пазарно говорене

Печалби

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25.02.2026 г., 22:56 ч. UTC

Пазарно говорене

Печалби

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25.02.2026 г., 22:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25.02.2026 г., 22:40 ч. UTC

Пазарно говорене

Печалби

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25.02.2026 г., 22:40 ч. UTC

Печалби

Karoon Energy Says Search for New CFO Well Advanced

25.02.2026 г., 22:39 ч. UTC

Печалби

Karoon Energy Says CFO Ray Church to Leave Company

25.02.2026 г., 22:39 ч. UTC

Печалби

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25.02.2026 г., 22:38 ч. UTC

Печалби

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.